After Hours Summary: LULU +6%, SCVL -8%, SONC -5% following earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: LULU +6.2%
Companies trading higher in after hours in reaction to news: ANW +31.6% (announces expiration of contractual deadline for approvals of previously announced share purchase agreement with shareholders of H.E.C. Europe; agreement has been terminated), CGG +5.8% (upgraded to Buy from Sell at Goldman), DXCM +4% (FDA granted a De Novo request for the G6 CGM System, the newest generation of CGM for people with diabetes ages 2 and up), RBC +2.6% (still checking -- Nasdaq/NYSE may cancel some trades), BB +1.5% (ahead of earnings), VNTR +0.6% (light volume; initiated with Outperform at BMO Capital Markets), NKE +0.6% (Darren Rovell reported that NFL owners have approved a 10 year extension to league's apparel deal with NKE), V +0.4% (light volume; initiated with Outperform at Bernstein)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: TEUM -11.7%, SCVL -7.9%, SONC -4.7%
Companies trading lower in after hours in reaction to news: APRI -26.7% (nanocap stock notably lower after commencing public offering of common stock and warrants), LAND -1.1% (prices 1.1 mln shares of common stock at $12.15 per share), NSPR -14.6% (proposed public offering of common stock), INPX -8.1% (files for $200 mln mixed securities shelf offering), ATOS -6% (files mixed securities shelf offering), D -1.6% (announced several initiatives to improve its near-term credit profile; commenced offering of 20 mln shares of common stock in connection with forward sale agreements; reaffirms guidance), PTCT -1.3% (commences public offering of 4 mln shares of common stock), GIS -1.2% (priced 22,727,273 share common stock offering at $44/share), GERN -0.8% (continued weakness after today's 14% decline), TSLA -0.4% (Moody's downgrades Tesla's corporate family rating to B3, senior notes to Caa1; Outlook is negative)
![]()
Gapping down
In reaction to disappointing earnings/guidance:
- FRAN -4.2%, PUMP -3.9%
Other news:
- LFIN -19% (continued weakness; to be removed from the Russell Indexes on March 28)
- OSTK -8.7% (to offer 4 mln shares of common stock)
- NVTA -6.4% (commences $50.0 mln common stock offering)
- LAND -6.3% (to sell shares of its common stock in an underwritten public offering)
- GERN -6.2% (cautious article from biotech blogger Adam Feuerstein)
- LMRK -3.3% (commenced offering of Series C Floating-to-Fixed Rate Cumulative Perpetual Redeemable Convertible Preferred Units representing limited partner interests)
- AUPH -3.3% (filed amendment to short form base shelf prospectus initially filed in January)
- MGNX -3% (commences 4.5 mln share common stock offering)
- BFAM -1.3% (priced public offering by certain of its stockholders of 4,606,062 shares of its common stock at $102.70/share)
- GIS -0.9% (proposes public offering of $1 bln in common stock in connection with pending acquisition of Blue Buffalo Pet Products; files debt securities and common stock shelf offering )
Analyst comments:
- CSIQ -1.5% (downgraded to Underweight from Neutral at JP Morgan)
- KIM -1.2% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- CHK -1% (downgraded to Underperform from Mkt Perform at Bernstein)
![]()
Gapping upGapping up
In reaction to strong earnings/guidance:
- RHT +6.2%, MKC +3.8%, CC +1.1%, WBAI +1%
M&A news:
- GGP +2.3% (BPY to acquire outstanding GGP common stock)
Other news:
- FENC +12.4% (receives breakthrough therapy designation by FDA for Pedmark)
- ITUS +8.5% (announces results of blinded prostate cancer study)
- ECR +6.2% (provides updated projections regarding Marcellus Condensate type curve; initiates strategic review)
- EKSO +2.4% (after closing near highs - up 35% on the day)
- QTNT +2.2% (reports concordance data for the MosaiQ blood grouping microarray generated in recent V&V head-to-head studies; CEO retires)
- ESPR +2.2% (positive top-line results from Phase 2 clinical study in patients with hypercholesterolemia)
- ATRS +1.4% (receives official minutes from Type A meeting with FDA regarding XYOSTED NDA)
- TVPT +1.2% (continued strength after Elliott disclosed stake)
- BLDP +0.8% (unit receives $1.9 mln follow-on order from US Army)
Analyst comments:
- ADMS +4.4% (initiated with a Buy at BofA/Merrill)
- BBT +2.1% (upgraded to Outperform from Market Perform at Wells Fargo)
- LRCX +1.8% (initiated with a Buy at Mizuho)
![]()